5381-78-2

Basic information

• Product Name: 1H-Benzimidazole,1-methyl-5-nitro-(9CI)
• Synonyms: 1H-Benzimidazole,1-methyl-5-nitro-(9CI);1-methyl-5-nitro-1H-1,3-benzimidazole;1H-benzimidazole, 1-methyl-5-nitro-;1-methyl-5-nitro-1H-benzimidazole;1-methyl-5-nitrobenzimidazole;1-methyl-5-nitro-benzimidazole;1-Methyl-5-nitro-1H-benzo[d]iMidazole;1-N-Methyl-5-nitroindazole
• CAS NO: 5381-78-2
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.162
• Product Categories: BENZIMIDAZOLE
• Mol File: 5381-78-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 210-212°
• Boiling Point: 358.6°Cat760mmHg
• Flash Point: 170.7°C
• Appearance: /
• Density: 1.42g/cm³
• Vapor Pressure: 2.52E-05mmHg at 25°C
• Refractive Index: 1.676
• PKA: 3.39±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole,1-methyl-5-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,1-methyl-5-nitro-(9CI)(5381-78-2)
• EPA Substance Registry System: 1H-Benzimidazole,1-methyl-5-nitro-(9CI)(5381-78-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5381-78-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7N3O2/c1-10-5-9-7-4-6(11(12)13)2-3-8(7)10/h2-5H,1H3

Upstream product

• 553-90-2 Dimethyl oxalate 
• 94-52-0 5-nitrobenzimidazole 
• 1632-83-3 1-Methylbenzimidazole 
• 74-88-4 methyl iodide 
• 94-52-0 6-nitro-1H-benzo[d]imidazole 
• 51-17-2 benzoimidazole 
• 124-38-9 carbon dioxide 
• 99-56-9 4-Nitrophenylene-1,2-diamine 

Downstream Products

• 10394-38-4 1-methyl-1H-benzo[d]imidazol-5-amine 
• 82040-15-1 3-Methyl-6-nitro-1-[2-(4-nitro-phenyl)-2-oxo-ethyl]-3H-benzoimidazol-1-ium; bromide 
• 85721-83-1 1-methyl-2-benzoyl-5-nitrobenzimidazole 
• 85510-68-5 1-methyl-3-benzoyl-5-nitro-2-(1-methyl-5-nitro-2-benzimidazolyl)-2-benzimidazol-4-ine 
• 82040-12-8 1-methyl-5-nitro-3-phenacylbenzimidazolium bromide 
• 66108-85-8 1-methyl-5-nitro-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 15965-66-9 2-chloro-1-methyl-5-nitro-1H-benzoimidazole 
• 82040-21-9 N-methyl-4-nitro-2-(4-phenyl-1H-imidazol-1-yl)aniline 
• 82040-26-4 N-methyl-4-nitro-2-(4-(4-nitrophenyl)-1H-imidazol-1-yl)aniline 
• 1190604-03-5 3-methyl-8-phenyl-3H-imidazo[4',5':3,4]benzo[c]isoxazole 
• 1190604-04-6 8-(4-chlorophenyl)-3-methyl-3H-imidazo[4,',5':3,4]benzo[c]isoxazole 
• 1234801-38-7 (2-{[(3E)-5-amino-2,2-dimethylfuran-3(2H)-ylidene]amino}-4-nitrophenyl)methylformamide 
• 1234801-39-8 (2-{[(4E)-2-amino-1-oxaspiro[4.5]dec-2-en-4-ylidene]amino}-4-nitrophenyl)methylformamide 
• 26530-93-8 1-methyl-6-amino-1H-benzo[d]imidazole 

Relevant articles and documents

Endogenous X-C=O species enable catalyst-free formylation prerequisite for CO2reductive upgrading

CO2, the main component of greenhouse gas, is currently developed as a promising surrogate of carbon feedstock. Among various conversion routes, CO2undergoing catalytic reduction can furnish hydrogen/energy carriers and value-added chemicals, while specific metal-containing catalysts or organocatalysts are often prerequisite for smooth proceeding of the involved reaction processes. In this work, both formic acid and N-containing benzoheterocyclic compounds (including various benzimidazoles, benzothiazole, and benzoxazole) along with silanols could be synthesized with high yields (>90%) from catalyst-free reductive upgrading of CO2under mild conditions (50 °C). The endogenous X-CO species, derived from the N-methyl-substituted amide-based solvent [Me2N-C(O)-R], especially PolarClean, and O-formyl group [O-C(O)-H] of in situ formed silyl formate, were found to play a prominent promotional role in the activation of the used hydrosilane for reductive CO2insertion, as demonstrated by density functional theory (DFT) calculations and isotopic labeling experiments. Moreover, reaction mechanisms and condition-based sensitivity assessment were also delineated.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

ANTIFUNGAL AGENTS

Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.